MedTrace Logo

Early Cancer Detection Test - Lung Cancer China

NCT04216511 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2020-01-02

No results posted yet for this study

Summary

Lung cancer is the most common cancer in China from both incidence and mortality rate point of view, with significantly lower 5-year survival rate than average. Early detection is the recognized solution. LDCT is more and more popular accepted as an effective screening methodology but leads to numerous indeterminate pulmonary nodules for physicians to distinguish too. The value of autoantibody test in risk assessing of IPNs as well as early detection of lung cancer in high risk population has been demonstrated in clinical practice and trial but mainly in Caucasian. Purpose of this study is to understand the sensitivity, specificity and accuracy of candidate autoantibodies, and consequently explore the autoantibody combination with best clinical performance in Chinese population.

Conditions

Interventions

DIAGNOSTIC_TEST

Tumor autoantibody detection

Level of a set of autoantibodies potentially relative with lung cancer will be tested for each of the participants.

Sponsors & Collaborators

  • Gene Tech (Shanghai) Company Limited

    collaborator UNKNOWN

  • Bai Chunxue

    lead OTHER

Principal Investigators

  • Chunxue Bai, MD · Fudan University

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-08-22
Primary Completion
2020-10-31
Completion
2021-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04216511 on ClinicalTrials.gov